It has been reported that CDH1 expression is notably elevated in prostate cancer cells (PC-3 and DU-145) upon treatment with SIT; the initiation and development of cancer correlate with the decrease in CDH1 expression, and the loss of function of this gene enhances invasive and metastatic capabilities, which in turn expedites tumor progression (63). The gene discussed is CDH1; the disease is neoplasm.